logo-loader

ReNeuron 'greatly encouraged' by US regulator feedback on CTX cell therapy trial

Published: 12:04 05 Jun 2017 BST

Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE) tells Proactive they've received positive guidance from the US regulator as they prepare to take their CTX cell therapy candidate for stroke victims into final-stage clinical trials.

ReNeuron has extended cash runway as it focuses on validating its exosome...

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors...

on 17/2/23